NeoGenomics, Inc. (NEO)

Over the past six months, NeoGenomics stock has experienced a decline. In October 2025, NeoGenomics reported its Q3 2025 total revenue with a year-over-year gain. NeoGenomics reported its fourth-quarter and full-year 2025 results on February 17, 2026. On February 25, 2026, NeoGenomics launched RaDaR ST. On March 16, 2026, NeoGenomics' PanTracer LBx received Medicare coverage. Analyst ratings were adjusted by Zacks Research, TD Cowen, William Blair, and Piper Sandler. Tudor Investment Corp ET AL cut its position in NeoGenomics in the third quarter of 2025. NeoGenomics is scheduled to report its first-quarter 2026 financial results on April 28, 2026.

NeoGenomics, Inc. experiences some demand seasonality for its products and services. The company typically observes a modest decline in the volume of its testing services during the summer vacation season. The company's revenue often increases over the course of the year, with a majority of its revenue generated later in the year.

NeoGenomics, Inc. is a clinical laboratory company specializing in cancer genetics diagnostic testing and information services, operating within the Healthcare sector. The company provides oncology-focused testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. Its services include Cytogenetics, FISH, Flow cytometry, Immunohistochemistry and digital imaging, Molecular testing and NGS, Morphologic analysis, and Pharma Services. NeoGenomics is expanding its portfolio with liquid biopsy and next-generation sequencing products, such as the RaDaR ST launch.

NeoGenomics, Inc. operates cancer-focused testing laboratories across the United States and the United Kingdom, serving various healthcare entities throughout the United States and Europe. In the United States, laboratories are located in Fort Myers and Tampa, Florida; Aliso Viejo and Carlsbad, California; Research Triangle Park, North Carolina; Houston, Texas; and Phoenix, Arizona. In the United Kingdom, NeoGenomics operates laboratories in Cambridge.

NeoGenomics' brand reputation has likely been positively influenced by its advancements in precision oncology and expanded service offerings. The launch of RaDaR ST positions NeoGenomics as a significant player in the MRD market. Medicare coverage for PanTracer LBx expands access for patients and validates the clinical utility of the product. The introduction of PanTracer Pro enhances the company's offerings for solid tumor therapy selection. Consistent growth in its clinical services division reinforces its leadership in oncology diagnostics.

NeoGenomics, Inc. has a significant institutional ownership presence. As of December 2025, 253 institutional investors held 131.92 million shares, representing 103.0% of NeoGenomics' outstanding shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, First Light Asset Management, LLC, and Greenhouse Funds LLLP.